Sera obtained in the immediate postmortem from 100 individuals, 64 neuropathologically diagnosed Alzheimer's disease (AD) cases and 36 nondemented controls, were analyzed for cholesterol, lipoproteins, apolipoproteins (Apo), and triglycerides. All individuals were ApoE genotyped, and the amounts of Abeta (N-40 and N-42) in cerebral cortex of AD and control subjects were determined. When compared to controls, AD individuals had significantly higher LDL cholesterol (P = 0.006), ApoB (P = 0.018), Abeta N-40 (P = 0.024) and Abeta N-42 (P < 0.001), and significantly lower HDL cholesterol (P = 0.040). There were positive correlations between the levels of serum total cholesterol (r = 0.359, P = 0.004), LDL cholesterol (r = 0.328, P = 0.008), and ApoB (r = 0.395, P = 0.001) to the amount of Abeta N-42 in AD brains, but not to Abeta N-40. These correlations were independent of ApoE genotype and were not seen in the control group. The present results suggest for the first time that elevated serum cholesterol, especially in the form of LDL, influences the expression of AD-related pathology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1006/bbrc.1998.9652 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of Resilience-Related Life Experiences on Variability on Age of Onset in Dominantly Inherited Alzheimer Disease.
Neurology
October 2024
From the Department of Nuclear Medicine (H.J.S., Jai-Hyuen Lee), Dankook University College of Medicine, Cheonan, Chung Nam; Department of Nuclear Medicine (J.S.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Neurology (R.J.B., J.J.L.-G., J.C.M., A.D.), Washington University School of Medicine, St. Louis, MO; Department of Clinical Epidemiology and Biostatistics (S.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Neurology (G.S.D.), Mayo Clinic College of Medicine and Science, Jacksonville, FL; Department of Neurology (J.P.C.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology (S.B.B.), University of Pittsburgh School of Medicine, PA; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney, Australia; Department of Cellular Neurology (M.J.), Hertie Institute for Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (M.J.), Tübingen; Department of Neurology (J.L.), Ludwig-Maximilians-Universität München; German Center for Neurodegenerative Diseases (J.L.), Munich; Munich Cluster for Systems Neurology (SyNergy) (J.L.), Germany; Department of Neurology (Jae-Hong Lee), University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea; Department of Pathology and Immunology (R.J.P.), Knight Alzheimer's Disease Research Center (R.J.P., J.H.), and Department of Neurology (R.J.P., J.H.), Washington University in St. Louis; Department of Psychiatry (C.C.), Washington University School of Medicine; Department of Psychological and Brain Sciences (J.H.), Washington University, St. Louis, MO; and Department of Neurology (S.P.S.), The Warren Alpert Medical School of Brown University, Butler Hospital, Providence, RI.
Article Synopsis
- The study examines the link between protective lifestyle factors and the age at symptom onset of autosomal dominant Alzheimer disease (ADAD), which is largely influenced by genetics, focusing on how resilience-related experiences may impact this relationship.
- The researchers analyzed data from the Dominantly Inherited Alzheimer Network, assessing both clinical and lifestyle factors in two groups: one looking at general resilience among people showing cognitive stability despite high pathology and another focusing on specific genetic timelines for ADAD.
- Findings from 320 participants indicate variations in age at onset among carriers based on lifestyle and resilience factors, revealing potential avenues for understanding how these influences might delay the onset of symptoms in genetically predisposed individuals.
Predicting Longitudinal Cognitive Decline and Alzheimer's Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers.
Cells
June 2024
Department of Biological Sciences, College of Natural Sciences, Kangwon National University, Chuncheon 24341, Republic of Korea.
The increasing burden of Alzheimer's disease (AD) emphasizes the need for effective diagnostic and therapeutic strategies. Despite available treatments targeting amyloid beta (Aβ) plaques, disease-modifying therapies remain elusive. Early detection of mild cognitive impairment (MCI) patients at risk for AD conversion is crucial, especially with anti-Aβ therapy.
View Article and Find Full Text PDFThe Hippocampal Subfield Volume Reduction and Plasma Biomarker Changes in Mild Cognitive Impairment and Alzheimer's Disease.
J Alzheimers Dis
April 2024
Department of Neurology, Th First Affiliated Hospital of Anhui Medical University, Hefei, China.
Background: The hippocampus consists of histologically and functionally distinct subfields, which shows differential vulnerabilities to Alzheimer's disease (AD)-associated pathological changes.
Objective: To investigate the atrophy patterns of the main hippocampal subfields in patients with mild cognitive impairment (MCI) and AD and the relationships among the hippocampal subfield volumes, plasma biomarkers and cognitive performance.
Methods: This cross-sectional study included 119 patients stratified into three categories: normal cognition (CN; N = 40), MCI (N = 39), and AD (N = 40).
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts.
Alzheimers Dement
April 2024
Center for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Introduction: For routine clinical implementation of Alzheimer's disease (AD) plasma biomarkers, fully automated random-access platforms are crucial to ensure reproducible measurements. We aimed to perform an analytical validation and to establish cutoffs for AD plasma biomarkers measured with Lumipulse.
Methods: Two cohorts were included.
Supplementation with Manihot esculenta Crantz (Cassava) leaves' extract prevents recognition memory deficits and hippocampal antioxidant dysfunction induced by Amyloid-β.
Nutr Neurosci
September 2024
Physiology Research Group, Stress, Memory and Behavior Lab, Universidade Federal do Pampa, Uruguaiana, Brazil.
Objective: The Manihot esculenta Crantz (Cassava) is a typical South American plant rich in nutrients and energetic compounds. Lately, our group has shown that non-pharmacological interventions with natural antioxidants present different neuroprotective effects on oxidative balance and memory deficits in AD-like animal models. Here, our objective was to evaluate the neuroprotective effects of Cassava leaves' extract (CAS) in an AD-like model induced by amyloid-beta (Aβ) 25-35 peptide.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!